Plain-English translation of NCT04910269 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing anti-coronavirus hyperimmune intravenous immunoglobulin (hIVIG)—a medication made from antibodies collected from people who have recovered from COVID-19—to see if it can help adults in the early stages of COVID-19 feel better faster. You would receive either one infusion of this medication or a placebo (fake treatment), along with your regular care. The study will track how you improve over the first week and beyond.
Early treatment might prevent COVID-19 from becoming severe enough to require hospitalization. Researchers want to know whether giving patients antibodies from recovered COVID-19 patients can help their own immune systems fight the virus more effectively in those critical early days.
You likely qualify if…
You likely don't qualify if…
You would come in for a single infusion appointment where you receive either the experimental treatment or placebo through an IV, along with your regular COVID-19 care. The study team would then check in with you on day 7 to see how you're doing, and continue follow-up through day 28 to track your recovery. The entire trial lasts about 4 weeks from the time you enroll.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States